The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Optineurin in Huntington's disease intranuclear inclusions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies have suggested that changes to OPTN are associated with the appearance of inclusion bodies and promote neurotoxicity in various neurodegenerative diseases [28, 71–77].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of optineurin in amyotrophic lateral sclerosis
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H., et al. (2010) · Nature · doi:10.1038/nature08971 · Cited by 1,265
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914
Research works printed but not linked: 37
- Anborgh, 2005, Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin, J. Biol. Chem., 280, 34840, 10.1074/jbc.M504508200 · DOI · Paper page
- Apweiler, 2011, Ongoing and future developments at the Universal Protein Resource, Nucleic Acids Res., 39, D214, 10.1093/nar/gkq1020 · DOI · Paper page
- Becher, 1998, Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length, Neurobiol. Dis., 4, 387, 10.1006/nbdi.1998.0168 · DOI · Paper page
- Belzil, 2011, Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis, Neurobiol. Aging, 32, e513, 10.1016/j.neurobiolaging.2010.10.001 · DOI
- Bond, 2011, Myosin VI and its binding partner optineurin are involved in secretory vesicle fusion at the plasma membrane, Mol. Biol. Cell, 22, 54, 10.1091/mbc.E10-06-0553 · DOI
- Chalasani, 2008, Focus on molecules: optineurin, Exp. Eye Res., 87, 1, 10.1016/j.exer.2007.10.021 · DOI
- Chalasani, 2009, Optineurin and its mutants: molecules associated with some forms of glaucoma, Ophthalmic Res., 42, 176, 10.1159/000232400 · DOI
- De Marco, 2006, Optineurin increases cell survival and translocates to the nucleus in a Rab8-dependent manner upon an apoptotic stimulus, J. Biol. Chem., 281, 16147, 10.1074/jbc.M601467200 · DOI · Paper page
- del Toro, 2009, Mutant huntingtin impairs post-Golgi trafficking to lysosomes by delocalizing optineurin/Rab8 complex from the Golgi apparatus, Mol. Biol. Cell, 20, 1478, 10.1091/mbc.E08-07-0726 · DOI · Paper page
- DiFiglia, 1997, Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain, Science, 277, 1990, 10.1126/science.277.5334.1990 · DOI · Paper page
- Doi, 2010, The RNA-binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases, Neurosci. Res., 66, 131, 10.1016/j.neures.2009.10.004 · DOI
- Gourfinkel-An, 1998, Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset, Neuroreport, 9, 1823, 10.1097/00001756-199806010-00028 · DOI
- Hattula, 2000, FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis, Curr. Biol., 10, 1603, 10.1016/S0960-9822(00)00864-2 · DOI · Paper page
- Hortobagyi, 2011, Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders, Acta Neuropathol., 121, 519, 10.1007/s00401-011-0813-3 · DOI
- Iida, 2011, Optineurin mutations in Japanese amyotrophic lateral sclerosis, J. Neurol. Neurosurg. Psychiatry
- Ito, 2011, Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease, Acta Neuropathol., 121, 555, 10.1007/s00401-011-0809-z · DOI
- Lagier-Tourenne, 2010, TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration, Hum. Mol. Genet., 19, R46, 10.1093/hmg/ddq137 · DOI · Paper page
- Li, 1998, Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains, Mol. Cell. Biol., 18, 1601, 10.1128/MCB.18.3.1601 · DOI · Paper page
- Maat-Schieman, 2007, Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease, Brain Pathol., 17, 31, 10.1111/j.1750-3639.2006.00040.x · DOI
- Maat-Schieman, 1999, Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain, J. Neuropathol. Exp. Neurol., 58, 129, 10.1097/00005072-199902000-00003 · DOI
- Millecamps, 2011, Screening of OPTN in French familial amyotrophic lateral sclerosis, Neurobiol. Aging, 32, 557, 10.1016/j.neurobiolaging.2010.11.005 · DOI
- Moreland, 2000, Identification of a transcription factor IIIA-interacting protein, Nucleic Acids Res., 28, 1986, 10.1093/nar/28.9.1986 · DOI
- Nagabhushana, 2010, Regulation of endocytic trafficking of transferrin receptor by optineurin and its impairment by a glaucoma-associated mutant, BMC Cell Biol., 11, 4, 10.1186/1471-2121-11-4 · DOI
- Osawa, 2011, Optineurin in neurodegenerative diseases, Neuropathology, 10.1111/j.1440-1789.2011.01199.x · DOI · Paper page
- Park, 2010, Impairment of protein trafficking upon overexpression and mutation of optineurin, PLoS One, 5, e11547, 10.1371/journal.pone.0011547 · DOI
- Park, 2006, Studies of optineurin, a glaucoma gene: Golgi fragmentation and cell death from overexpression of wild-type and mutant optineurin in two ocular cell types, Am. J. Pathol., 169, 1976, 10.2353/ajpath.2006.060400 · DOI · Paper page
- Rezaie, 2002, Adult-onset primary open-angle glaucoma caused by mutations in optineurin, Science, 295, 1077, 10.1126/science.1066901 · DOI · Paper page
- Rollinson, 2010, Analysis of optineurin in frontotemporal lobar degeneration, Neurobiol. Aging
- Rosas, 2008, Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity, Brain, 131, 1057, 10.1093/brain/awn025 · DOI · Paper page
- Sahlender, 2005, Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis, J. Cell Biol., 169, 285, 10.1083/jcb.200501162 · DOI · Paper page
- Schnell, 1999, Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue, J. Histochem. Cytochem., 47, 719, 10.1177/002215549904700601 · DOI · Paper page
- Schwamborn, 2000, Phorbol esters and cytokines regulate the expression of the NEMO-related protein, a molecule involved in a NF-kappa B-independent pathway, J. Biol. Chem., 275, 22780, 10.1074/jbc.M001500200 · DOI
- Sudhakar, 2009, NF-kappaB mediates tumor necrosis factor alpha-induced expression of optineurin, a negative regulator of NF-kappaB, PLoS One, 4, e5114, 10.1371/journal.pone.0005114 · DOI
- Sugihara, 2011, Screening for OPTN mutations in amyotrophic lateral sclerosis in a mainly Caucasian population, Neurobiol. Aging, 10.1016/j.neurobiolaging.2011.03.024 · DOI
- Swarup, 2010, Optineurin, a multifunctional protein involved in glaucoma, amyotrophic lateral sclerosis and antiviral signalling, J. Biosci., 35, 501, 10.1007/s12038-010-0056-9 · DOI
- Vonsattel, 2008, Huntington disease models and human neuropathology: similarities and differences, Acta Neuropathol., 115, 55, 10.1007/s00401-007-0306-6 · DOI · Paper page
- Ying, 2010, Posttranslational modifications, localization, and protein interactions of optineurin, the product of a glaucoma gene, PLoS One, 5, e9168, 10.1371/journal.pone.0009168 · DOI
Cited by
Aggrephagy: Selective Disposal of Protein Aggregates by Macroautophagy
Lamark, T., & Johansen, T. (2012) · International Journal of Cell Biology · doi:10.1155/2012/736905 · Cited by 497
Selective autophagy as a potential therapeutic target for neurodegenerative disorders
Scrivo, A., Bourdenx, M., Pampliega, O., & Cuervo, A. M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30238-2 · Cited by 355
Autophagy in Huntington disease and huntingtin in autophagy
Martin, D. D. O., Ladha, S., Ehrnhoefer, D. E., & Hayden, M. R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.09.003 · Cited by 350
Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates
Korac, J., Schaeffer, V., Kovacevic, I., Clement, A. M., Jungblut, B., Behl, C., Terzic, J., & Dikic, I. (2013) · Journal of Cell Science · doi:10.1242/jcs.114926 · Cited by 336
“OPTN has been shown to colocalize with protein inclusions in ALS (Maruyama et al., 2010), HD (Schwab et al., 2012) and many other neurodegenerative diseases (Osawa et al., 2011).”
BackgroundInfluentialAutophagy and neurodegeneration
Frake, R. A., Ricketts, T., Menzies, F. M., & Rubinsztein, D. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73944 · Cited by 332
“Optineurin can also bind to protein aggregates (56) and is sequestered in inclusions in ALS patients as well as in other neurodegenerative diseases (57, 58).”
BackgroundGenetics of amyotrophic lateral sclerosis: an update
Chen, S., Sayana, P., Zhang, X., & Le, W. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-28 · Cited by 326
Riguet, N., Mahul-Mellier, A.-L., Maharjan, N., Burtscher, J., Croisier, M., Knott, G., Hastings, J., Patin, A., Reiterer, V., Farhan, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26684-z · Cited by 118
Dysfunction of Optineurin in Amyotrophic Lateral Sclerosis and Glaucoma
Toth, R. P., & Atkin, J. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01017 · Cited by 114
Wise, J. P., & Cannon, J. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw133 · Cited by 20
Huang, K.-C., Gomes, C., Shiga, Y., Belforte, N., VanderWall, K. B., Lavekar, S. S., Fligor, C. M., Harkin, J., Hetzer, S. M., Patil, S. V., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01872-2 · Cited by 19
Metadata
- Authors
- Schwab, C., Yu, S., McGeer, E. G., & McGeer, P. L.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 506
- Issue
- 1
- Pages
- 149-154
- ISSN
- 0304-3940
- Cited by
- 47
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- the Pacific Alzheimer Research Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.